- September 6, 2024
- Posted by: legaleseblogger
- Category: Related News
legal-document-to-plain-english-translator/”>Try Free Now: Legalese tool without registration
Archer CGP Research Assays Now Facilitate HRD Assessment
Date: September 5, 2024
Introduction to New Developments in Cancer Research
CORALVILLE, Iowa — (BUSINESS WIRE) — The landscape of cancer research continues to evolve as Integrated DNA Technologies (IDT) announces a significant expansion in its Archer portfolio of comprehensive genomic profiling (CGP) solutions. The inclusion of homologous recombination deficiency (HRD) assessment marks a pivotal advancement aimed at enhancing the identification of critical biomarkers in cancer research. This development empowers laboratories to optimize their resources through highly customizable solutions available in various formats.
Understanding HRD Assessment and Its Importance
As cancer research increasingly focuses on precision medicine, the need for efficient and comprehensive biomarker assessments has never been more crucial. The newly introduced HRD assessment can be integrated as a standalone assay, included as a supplemental module for existing tests, or seamlessly incorporated into an Archer NGS panel. This versatility allows laboratories to remain competitive and efficient while meeting the growing demands of cancer biomarker analysis.
The HRD assessment works in tandem with other Archer capabilities such as microsatellite instability (MSI) assessments and tumor mutational burden (TMB) evaluations. This combination creates a robust and flexible CGP solution tailored specifically to the laboratory’s requirements allowing for optimal resource utilization—essentially enabling labs to derive more insights with less input.
The Expanded Archer NGS Capabilities
Key Features of the New HRD Assessment
IDT’s innovative HRD module is available across several product lines:
- VARIANT Plex™ HRD Module: This module can be used as a spike-in to other Archer panels or operated independently.
- VARIANT Plex™ Complete Solid Tumor v2 Panel: This upgrade allows for the HRD assessment alongside existing capabilities.
- VARIANT Plex™ Pan Solid Tumor v2 Panel: Further expands Archer’s existing capabilities to include HRD assessments, ensuring comprehensive profiling of various tumor types.
By employing Archer’s proprietary Anchored Multiplex PCR (AMP™) chemistry and Archer Analysis, the new HRD module enhances the application of precision medicine, offering labs a customizable solution that aligns with their specific solid tumor research needs.
Innovations and Insights from IDT
Steve Wowk, Vice President/General Manager of the Gene Reading Business Unit at IDT, emphasizes the transformational potential of the new HRD module, stating, “Our latest innovation enables laboratories to extract the most comprehensive biomarker content from a single, low-input sample.” He highlights IDT’s commitment to providing timely, accurate solutions that support cancer research and address the common challenges laboratories face, particularly in terms of technical and resource limits.
Incoming wave of comprehensive genomic profiling: The increasing popularity of CGP solutions is transforming cancer research by allowing rapid identification of essential cancer biomarkers. IDT’s diverse array of CGP solutions includes pre-designed and customizable RNA- and DNA-based panels, making it easier for labs to adapt their targets as needed without incurring significant changes to established protocols.
Leveraging Technology with AI legalese decoder
Navigating the complex landscape of genomic research often includes grappling with regulatory and intellectual property issues. Researchers are frequently confronted with legal documents that can be challenging to interpret. This is where the AI legalese decoder can prove invaluable.
Simplifying legal Complexities
By utilizing AI legalese decoder, researchers can gain clarity in understanding legal obligations and emerging trends within the regulatory frameworks surrounding genomic research. The tool decodes complicated legal jargon and synthesizes key information quickly, allowing laboratories to focus on what they do best: research and innovation.
Conclusion: A New Era in Cancer Research
For more insights about the HRD assessment capabilities and IDT’s comprehensive genomic profiling solutions, please visit IDT’s website.
About Integrated DNA Technologies (IDT)
With over 35 years of industry experience, IDT has solidified its position as a leader in genomics, particularly in the manufacturing of oligonucleotides. Since its founding in 1987, IDT has transitioned from a prominent oligo manufacturer to a comprehensive genomics solutions provider. The company’s offerings cover various application areas, including next-generation sequencing, CRISPR genome editing, and RNA interference.
IDT’s commitment to accelerating genomic research was further amplified in December 2022 with the acquisition of Archer™ NGS Research Assays. By combining established technologies with innovative solutions, IDT aims to facilitate groundbreaking advancements in cancer research.
Global Reach and Commitment
IDT continues to support laboratories worldwide, with manufacturing facilities located across the United States and internationally, including in Belgium and Singapore. As a proud member of the Danaher family, IDT leverages the vast expertise and resources available to provide its customers with cutting-edge solutions.
For more information on IDT’s products and offerings, visit IDT’s official website and connect with the company on popular social media platforms.
Disclaimer
RUO — For research use only. Not for use in diagnostic procedures. IDT products are not intended for clinical applications unless otherwise agreed to in writing.
Contact Information
Kristina Sarenas
Director of PR
800-328-2661 (USA & Canada)
+1 319-626-8400 (outside USA)
[email protected]
legal-document-to-plain-english-translator/”>Try Free Now: Legalese tool without registration
****** just grabbed a